Exchange: NASDAQ·Updated 08:19 AM EDT
LUCD logo

LUCD Lucid Diagnostics Inc

$0.979
$0.0278
(2.92%)
Pre-Market
Prev Close $0.9512
Reported EarningsAug 13
Mkt Cap$193.33M
Vol1,087.00

About LUCD

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.
50

Neutral Sentiment

How do you feel about LUCD?

Advertisement|Remove ads.